Display options
Cite
Vorbeck CS, Vogelius IR, Banner-Voigt MLVC, et al. Survival and failure types after radiation therapy of vulvar cancer. Clin Transl Radiat Oncol. 2017;5:20-27doi: 10.1016/j.ctro.2017.06.002.
Vorbeck, C. S., Vogelius, I. R., Banner-Voigt, M. L. V. C., Mathiesen, H. F., & Mirza, M. R. (2017). Survival and failure types after radiation therapy of vulvar cancer. Clinical and translational radiation oncology, 520-27. https://doi.org/10.1016/j.ctro.2017.06.002
Vorbeck, Christina Steen, et al. "Survival and failure types after radiation therapy of vulvar cancer." Clinical and translational radiation oncology vol. 5 (2017): 20-27. doi: https://doi.org/10.1016/j.ctro.2017.06.002
Vorbeck CS, Vogelius IR, Banner-Voigt MLVC, Mathiesen HF, Mirza MR. Survival and failure types after radiation therapy of vulvar cancer. Clin Transl Radiat Oncol. 2017 Jul 07;5:20-27. doi: 10.1016/j.ctro.2017.06.002. eCollection 2017 Aug. PMID: 29594213; PMCID: PMC5833899.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Radiat Oncol. 2017 Jul 07;5:20-27. doi: 10.1016/j.ctro.2017.06.002. eCollection 2017 Aug.

Survival and failure types after radiation therapy of vulvar cancer.

Clinical and translational radiation oncology

Christina Steen Vorbeck, Ivan Richter Vogelius, Marie Louise Vorndran Cøln Banner-Voigt, Hanne From Mathiesen, Mansoor Raza Mirza

Affiliations

  1. Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark.

PMID: 29594213 PMCID: PMC5833899 DOI: 10.1016/j.ctro.2017.06.002

Abstract

BACKGROUND AND PURPOSE: Describe the survival rates and distribution of events on competing failure types in vulvar carcinoma after treatment with chemoradiation (CRT) or radiation (RT) alone.

MATERIAL AND METHODS: We included patients with vulvar carcinoma treated with CRT or RT between 2009 and 2014. Survival was estimated using the Kaplan-Meier method. We performed a competing risk analysis and included five competing events: loco-regional failure (LRF), distant metastasis, LRF plus distant metastasis, and death without evidence of disease, with the remaining patients denoted alive without evidence of disease.

RESULTS: 87 patients were treated. Progression free survival (PFS) and overall survival (OS) at 3 years were 40% and 57%, respectively. 41.3% of patients relapsed, most often loco-regionally. We saw significantly worse PFS and OS for patients older than 68 (

CONCLUSIONS: LRF was the most common event. PFS and OS were inferior for elderly patients and patients treated definitively. A better understanding of these differences may be used to define risk adapted treatment strategies.

Keywords: Chemoradiation; Elderly; Failure types; Radiation; Vulvar cancer

References

  1. Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):381-9 - PubMed
  2. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002225 - PubMed
  3. Am J Clin Oncol. 2013 Jun;36(3):279-82 - PubMed
  4. Gynecol Oncol. 2011 Sep;122(3):509-14 - PubMed
  5. Cancer. 1995 May 1;75(9):2289-94 - PubMed
  6. Gynecol Oncol. 2004 Mar;92(3):856-65 - PubMed
  7. Gynecol Oncol. 2011 Jan;120(1):101-7 - PubMed
  8. Surgeon. 2016 Aug;14 (4):202-12 - PubMed
  9. Lancet Oncol. 2005 Feb;6(2):112-7 - PubMed
  10. Int J Gynecol Pathol. 2006 Jan;25(1):22-9 - PubMed
  11. Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):279-83 - PubMed
  12. Gynecol Oncol. 2010 May;117(2):312-6 - PubMed
  13. Gynecol Oncol. 2012 Mar;124(3):529-33 - PubMed
  14. Cancer. 2000 Jul 1;89(1):116-22 - PubMed
  15. Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1007-13 - PubMed
  16. Clin Cancer Res. 2012 Apr 15;18(8):2127-9 - PubMed
  17. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):551-60 - PubMed
  18. Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):79-85 - PubMed
  19. J Skin Cancer. 2011;2011:951250 - PubMed
  20. Int J Cancer. 2008 Jun 15;122(12):2827-34 - PubMed
  21. Eur J Cancer. 2011 Oct;47(15):2315-21 - PubMed

Publication Types